Additional data made available concerning first trimester dolutegravir use

Researchers from the Assistance Publique-Hopitaux de Paris have published national surveillance data of first-trimester exposure to dolutegravir, raltegravir or elvitegravir in pregnancy, adding to the growing body of evidence available for integrase strand transfer inhibitors. More information can be found here.